Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|32|5775-5791

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.32, 2013-10, pp. : 5775-5791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis

By Geisthövel Franz   Rabe Thomas  

Reproductive BioMedicine Online, Vol. 14, Iss. 4, 2007-04 ,pp. : 522-535

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 1, 2014-06 ,pp. : 70-83

Bentham Science Publishers

Access to resources Recommend Favorite

Translational Insight Into Polycystic Ovary Syndrome (PCOS) From Female Monkeys with PCOS-like Traits

By  

Current Pharmaceutical Design, Vol. 22, Iss. 36, 2016-10 ,pp. : 5625-5633

Bentham Science Publishers

Access to resources Recommend Favorite

Simvastatin reduces serum testosterone (T) levels in women with polycystic ovary syndrome (PCOS)

By  

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The Suitability of Polycystic Ovary Syndrome-Specific Questionnaires for Measuring the Impact of PCOS on Quality of Life in Clinical Trials

By Malik-Aslam Aysha   Reaney Matthew D.   Speight Jane  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 440-446

Blackwell Publishing

Access to resources Recommend Favorite